Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers

Neoplasia

Volumn 9, Issue 6, 2007, Pages 464-470

  You, Zongbing ^a   Dong, Ying ^a   Kong, Xiangtian ^b   Zhang, Yi ^a   Vessella, Robert L ^c   Melamed, Jonathan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Interleukin 17RC; Prostate cancer; Protein isoforms; Tissue microarray

Indexed keywords

ANDROGEN; INTERLEUKIN 17 RECEPTOR LIKE PROTEIN; ISOPROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; EMBRYO; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 34250882682     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07109     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. 2) prostate cancer. The Zoladex Study Group. JAMA 265, 618-621.
3. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, and Vessella RL (2003). Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34, 646-653.
4. De La Taille A, Vacherot F, Salomon L, Druel C, Gil Diez De Medina S, Abbou C, Buttyan R, and Chopin D (2001). Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 4, 204-212.
5. Craft N and Sawyers CL (1999). Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 17, 421-427.
6. Hirano D, Okada Y, Minei S, Takimoto Y, and Nemoto N (2004). Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45, 586-592.
7. Moseley TA, Haudenschild DR, Rose L, and Reddi AH (2003). Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14, 155-174.
8. Haudenschild D, Moseley T, Rose L, and Reddi AH (2002). Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 277, 4309-4316.
9. Haudenschild DR, Curtiss SB, Moseley TA, and Reddi AH (2006). Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate 66, 1268-1274.
10. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, and Reddi AH (2006). Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. Cancer Res 66, 175-183.
11. Lee MS, Garkovenko E, Yun JS, Weijerman PC, Peehl DM, Chen LS, and Rhim JS (1994). Characterization of adult human prostatic epithelial cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective SV40 genome. Int J Oncol 4, 821-830.
12. Bello D, Webber MM, Kleinman HK, Wartinger DD, and Rhim JS (1997). Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18, 1215-1223.
13. You Z, DuRaine G, Tien JY, Lee C, Moseley TA, and Reddi AH (2005). Expression of interleukin-17B in mouse embryonic limb buds and regulation by BMP-7 and bFGF. Biochem Biophys Res Commun 326, 624-631.
14. Haudenschild DR, Palmer SM, Moseley TA, You Z, and Reddi AH (2004). Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64, 8276-8284.
15. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, and McGuire WL (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85, 200-206.
16. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, and Peschon J (2006). Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177, 36-39.